Published in Semin Oncol on February 01, 2010
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84
Predicting cancer prognosis using interactive online tools: a systematic review and implications for cancer care providers. Cancer Epidemiol Biomarkers Prev (2013) 0.97
Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer (2011) 0.90
A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer. Br J Cancer (2010) 0.82
Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis (2011) 0.81
hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther (2016) 0.77
The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. J Cancer Res Clin Oncol (2013) 0.76
Predicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data Base. J Am Coll Surg (2015) 0.75
NCAPH plays important roles in human colon cancer. Cell Death Dis (2017) 0.75
Validation of a modified clinical risk score to predict cancer-specific survival for stage II colon cancer. Cancer Med (2014) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol (2001) 6.23
Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol (2005) 4.31
Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev (2008) 2.60
Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol (2001) 1.98
Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol (2007) 1.05
Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol (1994) 0.95
Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw (2003) 0.86
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 6.20
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol (2007) 4.14
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (2010) 3.67
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2009) 3.38
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (2013) 3.18
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol (2007) 3.00
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer (2008) 2.55
Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. Eur J Haematol (2005) 2.47
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol (2007) 2.41
Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park) (2014) 2.21
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist (2009) 1.99
Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer (2008) 1.94
Differences in cancer incidence among Indians in Alaska and New Mexico and U.S. Whites, 1993-2002. Cancer Epidemiol Biomarkers Prev (2006) 1.94
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.83
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause (2007) 1.78
Randomized phase II designs. Clin Cancer Res (2009) 1.73
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol (2008) 1.65
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol (2005) 1.63
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology (2010) 1.62
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause (2009) 1.61
Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol (2005) 1.52
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Symptom control trials: a 20-year experience. J Support Oncol (2007) 1.48
Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43
Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev (2004) 1.41
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol (2010) 1.40
Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal (2008) 1.34
A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage (2012) 1.26
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Integrating biomarkers in clinical trials. Expert Rev Mol Diagn (2011) 1.24
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther (2007) 1.20
Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park) (2008) 1.18
Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw (2013) 1.18
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer (2009) 1.13
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer (2012) 1.12
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep (2013) 1.12
Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer (2010) 1.12
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. J Clin Oncol (2014) 1.10
Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res (2003) 1.08
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. Clin Colorectal Cancer (2005) 1.07
Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res (2003) 1.07
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer (2005) 1.06
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs (2008) 1.04
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs (2014) 1.03
Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer (2008) 1.03
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer (2012) 1.03
Disease-free survival in colon cancer: still relevant after all these years! J Clin Oncol (2013) 1.01
Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res (2009) 0.99
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Am J Clin Oncol (2017) 0.99
Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer (2005) 0.98
N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer (2005) 0.98
Treatment options for advanced pancreatic cancer: a review. Expert Rev Anticancer Ther (2012) 0.98
Adjuvant chemotherapy for stage III colon cancer: does timing matter? Dis Colon Rectum (2011) 0.97
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer (2014) 0.96
Physician/patient decision aids for adjuvant therapy. J Clin Oncol (2005) 0.96
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist (2011) 0.96
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol (2004) 0.96
Patterns of diagnosis for colorectal cancer: screening detected vs. symptomatic presentation. Dis Colon Rectum (2008) 0.95
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer (2007) 0.95
End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol (2007) 0.95
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer (2008) 0.94
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol (2004) 0.94
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer (2004) 0.93
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer (2011) 0.92
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs (2010) 0.92
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist (2011) 0.91
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer (2011) 0.91
Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol (2010) 0.91
Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol (2012) 0.91
Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol (2010) 0.90
Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer (2011) 0.90